Everything below concerns 三重激动剂. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
== Function == Living cells translate DNA sequences into RNA sequences and then into protein sequences. Proteins are chains of amino acids, such as tyrosine. As the protein grows, each amino acid is added to the end with the help of an adapator molecule called transfer RNA (tRNA). Each amino acid has its own tRNA (called tRNATyr in the case of tyrosine), and tyrosyl-tRNA synthetase is an enzyme that attaches tyrosine to tRNATyr, so that it can be then used in this translation process. Aminoacyl-tRNA synthetases catalyze the aminoacylation of transfer RNA (tRNA) by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine.
Intravascular hemolysis describes hemolysis that happens mainly inside the vasculature. As a result, the contents of the red blood cell are released into the general circulation, leading to hemoglobinemia and increasing the risk of ensuing hyperbilirubinemia. Intravascular hemolysis may occur when red blood cells are targeted by autoantibodies, leading to complement fixation, or by damage by parasites such as Babesia. Additionally, thrombotic microangiopathy (TMA) can result in hemolysis of red blood cells. TMA is frequently observed in aHUS patients where clots form in the small vessels of the kidney resulting in damaged red blood cells as they attempt to pass through the restricted vessels.
The advance voting on 1 February saw many complaints of issues with the election process. One reported issue, which was also seen in the previous election, was that election officials wrote wrong codes on ballot envelopes, raising concerns that the ballots might end up in a different district and therefore be counted for the wrong candidate. Voters also reported missing or incorrect on information boards at some polling stations. This included cases where a candidate's information was entirely missing from the information board. In some of these cases, it was reported that polling station officials initially claimed that the missing candidates had been disqualified and only later rectified the mistake. Those affected included candidates from the People's Party, Pheu Thai Party, and Democrat Party.
AAV is of particular interest to gene therapists due to its apparent limited capacity to induce immune responses in humans, a factor which should positively influence vector transduction efficiency while reducing the risk of any immune-associated pathology. AAV is not considered to have any known role in disease. However, host immune system response and immune tolerance reduce the efficacy of AAV-mediated gene therapy. Host immune response has been shown to respond to the AAV vectors, the transduced cells, and the transduced proteins. The immune response can be subdivided into two categories: innate and adaptive, the latter of which is divided into humoral and cell-mediated.
Actinides are typical metals. All of them are soft and have a silvery color (but tarnish in air), relatively high density and plasticity. Some of them can be cut with a knife. Their electrical resistivity varies between 15 and 150 μΩ·cm. The hardness of thorium is similar to that of soft steel, so heated pure thorium can be rolled in sheets and pulled into wire. Thorium is nearly half as dense as uranium and plutonium, but is harder than either of them. All actinides are radioactive, paramagnetic, and, with the exception of actinium, have several crystalline phases: plutonium has seven, and uranium, neptunium and californium three. The crystal structures of protactinium, uranium, neptunium and plutonium do not have clear analogs among the lanthanides and are more similar to those of the 3d-transition metals. All actinides are pyrophoric, especially when finely divided, that is, they spontaneously ignite upon reaction with air at room temperature. The melting point of actinides does not have a clear dependence on the number of f-electrons. The unusually low melting point of neptunium and plutonium (~640 °C) is explained by hybridization of 5f and 6d orbitals and the formation of directional bonds in these metals.
Sources: en.wikipedia.org
In physics, the first law of thermodynamics is an expression of the conservation of total energy of a system. The increase of the energy of a system is equal to the sum of work done on the system and the heat added to that system:
The Republic of South Africa was established in 1961. The only change made to the composition of the Parliament was the substitution of the State President for the Queen. A few significant changes were made later:
火 (huǒ, fire) e.g.: 烷 (wán, alkane), common for hydrocarbons 酉 (yǒu, ritual wine vessel) e.g.: 酮 (tóng, ketone), common for oxygenated functionalities 艸 (cǎo, grass) e.g. 苯 (běn, benzene, phenyl), common for aromatic compounds and terpenes 肉 (ròu, meat, flesh) e.g. 腙 (zōng, hydrazone), common for nitrogen-containing functionalities Additionally, the mouth radical (口, kǒu) is affixed to characters that are used for their sound only. This occurs often in the transliteration of the names of heterocyclic compounds, (e.g., 吡啶, "bǐdìng", pyridine). These characters are also used for the transliteration of non-chemical terms from foreign languages.
== Career and research == Tschöp obtained an M.D. from LMU Munich (1993), where he worked as a clinician (1994–1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999–2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002–2003). He was a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003–2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009–2011). He was Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018). Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today's most frequently cited metabolism research papers. It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.
== Etymology == The word skin originally only referred to dressed and tanned animal hide and the usual word for human skin was hide. Skin is a borrowing from Old Norse skinn "animal hide, fur", ultimately from the Proto-Indo-European root *sek-, meaning "to cut" (probably a reference to the fact that in those times animal hide was commonly cut off to be used as garment).
Sources: en.wikipedia.org
The other measurement, based on the Brønsted–Lowry definition, is the acid dissociation constant (Ka), which measures the relative ability of a substance to act as an acid under the Brønsted–Lowry definition of an acid. That is, substances with a higher Ka are more likely to donate hydrogen ions in chemical reactions than those with lower Ka values.
=== Skeleton === Because feathers are often associated with birds, feathered dinosaurs are often touted as the missing link between birds and dinosaurs. However, the multiple skeletal features also shared by the two groups represent another important line of evidence for paleontologists. Areas of the skeleton with important similarities include the neck, pubis, wrist (semi-lunate carpal), arm and pectoral girdle, furcula (wishbone), and breast bone. Comparison of bird and dinosaur skeletons through cladistic analysis strengthens the case for the link.
== Patent infringement lawsuit == In 2002, MDS (at that time owner of SCIEX) and joint venture partner Applied Biosystems, won a $52.6 million judgement against Micromass UK for infringement of U.S. Patent No. 4,963,736 that describes a method of ion focusing using RF fields and gas collisions.
On 1 June 2020, the United States Pharmacopeia (USP) decided to cancel the proposal to include recombinant technology for endotoxin testing in chapter 85, Bacterial Endotoxins, and start the development of a separate chapter that expands on the use, validation, and comparability of endotoxin tests based on recombinantly derived reagents. A separate guidance-only chapter 1085.1 was proposed by the USP, though comments and feedback published on 11 December 2020 show that pharmaceutical companies and the FDA did not support this chapter and requested compendial status. In response, USP subsequently developed General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents, which provides compendial requirements for endotoxin testing using non-animal-derived reagents such as recombinant factor C (rFC). Chapter <86> became official in USP–NF in May 2025, establishing rFC as a pharmacopeially recognized alternative to the Limulus amebocyte lysate test.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.